Boule Diagnostics has received an order for 245 instruments – to date the company’s largest single instrument order. The buyer is Piramal Healthcare, one of the company’s Indian distributors. India is a large and rapidly growing market for blood cell counting and the order offers good potential for Boule Diagnostics to continue to take market shares in the Indian market.
Ernst Westman, CEO of Boule Diagnostics AB comments;
“India is one of our major markets and we have, together with our Indian distributors, devoted considerable effort to advance our positions. This is beginning to bear fruit and it is gratifying that we in a few months have received orders totaling more than 350 instruments to one of the distributors in India. The instruments are the basis of our systems, and as the instrument sales increase, we also expect an increase in sales of consumables, which will also result in higher margins. However, we believe that this order meets the expectations we have for growth in India and will not affect our fundamental view of the business at large.”
Piramal Healthcare is one of India’s largest healthcare company and one of the world’s largest contract manufacturers in the pharmaceutical industry. The sale was facilitated by collaboration with EKN, a Swedish government agency that supports export companies and the internationalization of Swedish business.
For more information, please contact:
Ernst Westman, President CEO of Boule Diagnostics AB, telephone +46 708-60 88 63
The information disclosed in this press release is such that Boule Diagnostics AB is required to make this information public in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for publication on April 20, 2012 at 08.00 am (CET).
TO THE EDITORS
About Boule Diagnostics AB
Boule Diagnostics AB is a fast-growing diagnostics company, developing and manufacturing systems and consumables for automated blood cell counting (hematology diagnostics) for healthcare providers worldwide. The company is primarily focused on small and medium-sized hospitals, clinics and laboratories in outpatient care as well as other diagnostics companies in both human and veterinary hematology. The group is comprised of operating subsidiaries in Sweden, the US and China. Boule Diagnostics’ share is, since 2011, traded on NASDAQ OMX Nordic. http://www.boule.se